Switching to once-daily Triumeq maintains HIV viral suppression

ViiV Healthcare has announced 24-week data from the Phase IIIb/IV STRIIVING study evaluating the efficacy, safety and tolerability of switching from an antiretroviral therapy (ART) to Triumeq in virologically suppressed adults with HIV-1.

The study included adults who remained on their existing ART to 24 weeks.

STRIIVING met its primary endpoint, demonstrating that viral suppression was non-inferior for patients switching to once-daily Triumeq (abacavir/dolutegravir/lamivudine). No patients had protocol defined virologic failure and therefore no patients were evaluated for treatment-emergent resistance in either arm (ITTe). 

Treatment satisfaction score improved in patients switching to Triumeq

Furthermore, statistically, the treatment satisfaction score improved significantly more for those patients switching to Triumeq from their established regimen, as assessed by the HIV Treatment Satisfaction Questionnaire.

“For clinicians, choosing among antiretroviral therapies now involves balancing efficacy with factors such as tolerability, dosing, ability to use with other medications, and resistance profile. These data support the use of once-daily abacavir/dolutegravir/lamivudine as a treatment option in the switch setting for appropriate patients,” said John Pottage, MD, Chief Scientific and Medical Officer, ViiV Healthcare.  

Patients switching to Triumeq reported more adverse events (AEs) leading to withdrawal compared with those who continued on their established regimen. The majority of these AEs were Grade I & 2. The most common AEs (≥ 5%) reported in patients switched to the Triumeq arm included cough, diarrhoea, fatigue, headache, nausea and upper respiratory tract infection.